4 Outpatient & Home Healthcare Stocks in Focus Amid Industry Tailwinds
An aging population and growing telehealth and AI adoption support the Zacks Medical - Outpatient and Home Healthcare industry. DVA, LFST, OPCH and AVAH stand to benefit.
LFST - LifeStance Health Group, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$13.29
DETAILS
HIGH:
$19.00
LOW:
$9.00
MEDIAN:
$13.00
CONSENSUS:
$13.29
UPSIDE:
7.96%
Stock News
Bet on These 5 Low-Leverage Stocks as Bond Yields Dip
Low-leverage stocks like NVIDIA and Valero Energy could offer investors resilience amid market volatility and uncertainty.
LifeStance Health Group (LFST) Is Up 3.44% in One Week: What You Should Know
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
5 Low-Leverage Stocks to Buy as High Oil Prices Shake Investor Confidence
High oil prices and market volatility spotlight five low-leverage stocks with strong earnings growth and resilient balance sheets.
LifeStance Health (LFST) Upgraded to Buy: Here's Why
LifeStance Health (LFST) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
LifeStance Health Group, Inc. (LFST) Soars to 52-Week High, Time to Cash Out?
LifeStance Health (LFST) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
LifeStance Survey Finds Women Want Mental Healthcare Built Into Perimenopause and Menopause Care
One in Three Women Don't Know Perimenopause Can Cause Anxiety, Depression and Mood Changes; Majority Who Seek Mental Healthcare Find It Helpful SCOTTSDALE, Ariz., Aug. 11, 2026 /PRNewswire/ -- A LifeStance Health survey of 1,000 women experiencing perimenopause or menopause released today reveals this life stage carries an unexpected mental health toll, as one in three women (33%) report being unaware that perimenopause can cause mental health-related symptoms.
LifeStance Health Group (NASDAQ:LFST) Sets New 1-Year High After Analyst Upgrade
LifeStance Health Group, Inc. (NASDAQ: LFST - Get Free Report)'s stock price reached a new 52-week high during trading on Monday after BTIG Research raised their price target on the stock from $15.00 to $16.00. BTIG Research currently has a buy rating on the stock. LifeStance Health Group traded as high as $12.06 and last traded
LifeStance Health Group Q2 Earnings Call Highlights
LifeStance Health Group NASDAQ: LFST reported second-quarter results that exceeded its prior expectations, driven by higher visit volumes, increased revenue per visit and continued clinician productivity gains. The outpatient mental health provider raised its full-year revenue, Center Margin and adjusted EBITDA guidance.
LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript
LifeStance Health Group, Inc. (LFST) Q2 2026 Earnings Call Transcript
LifeStance Health Group (LFST) Tops Q2 Earnings and Revenue Estimates
LifeStance Health Group (LFST) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to a loss of $0.01 per share a year ago.
LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook
SCOTTSDALE, Ariz., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (Nasdaq: LFST), one of the nation's largest providers of outpatient mental healthcare, today announced financial results for the second quarter ended June 30, 2026.
LifeStance to Host Second Quarter 2026 Earnings Conference Call on August 6, 2026
SCOTTSDALE, Ariz., July 16, 2026 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation's largest providers of outpatient mental healthcare, will issue its second quarter 2026 earnings release before the market opens on Thursday, August 6, 2026.
Are You Looking for a Top Momentum Pick? Why LifeStance Health Group (LFST) is a Great Choice
Does LifeStance Health Group (LFST) have what it takes to be a top stock pick for momentum investors? Let's find out.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
4 Outpatient Home Health Stocks Benefiting From Industry Trends
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
Wall Street Analysts Predict a 37.26% Upside in LifeStance Health (LFST): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 37.3% in LifeStance Health (LFST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Bears are Losing Control Over LifeStance Health (LFST), Here's Why It's a 'Buy' Now
After losing some value lately, a hammer chart pattern has been formed for LifeStance Health (LFST), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
LifeStance Health Group, Inc. (LFST) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Earnings Estimates Rising for LifeStance Health (LFST): Will It Gain?
LifeStance Health Group (LFST) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Price Targets
LifeStance price target raised to $19 from $16 at BTIG
$19.00
(was $12.56)
BTIG
LifeStance price target raised to $13 from $10 at Morgan Stanley
$13.00
(was $10.77)
Morgan Stanley
LifeStance price target raised to $13 from $10 at BMO Capital
$13.00
(was $10.66)
BMO Capital
LifeStance price target raised to $16 from $15 at BTIG
$16.00
(was $10.66)
BTIG
LifeStance price target raised to $15 from $12 at BTIG
$15.00
(was $10.81)
BTIG
LifeStance price target raised to $13 from $11 at Canaccord
$13.00
(was $11.34)
Canaccord Genuity
LifeStance price target raised to $13 from $9 at Barclays
$13.00
(was $10.88)
Barclays
LifeStance price target raised to $13 from $11 at KeyBanc
$13.00
(was $10.71)
Steve Dechert
·
KeyBanc
Goldman Sachs Starts Lifestance Health Group (LFST) at Neutral
$9.00
(was $7.64)
Scott Fidel
·
Goldman Sachs
LifeStance price target raised to $11 from $10 at Canaccord
$11.00
(was $8.85)
Canaccord Genuity
LifeStance price target raised to $10 from $8 at BMO Capital
$10.00
(was $7.41)
BMO Capital
LifeStance price target raised to $11 from $10 at BTIG
$11.00
(was $7.07)
David Larsen
·
BTIG
LifeStance price target raised to $8.50 from $6.50 at KeyBanc
$8.50
(was $7.30)
Steve Dechert
·
KeyBanc
LifeStance price target raised to $9 from $8 at Canaccord
$9.00
(was $7.30)
Richard Close
·
Canaccord Genuity
LifeStance price target raised to $10 from $9 at BTIG
$10.00
(was $6.77)
BTIG
LifeStance initiated with an Overweight at Barclays
$8.00
(was $6.41)
Peter Warendorf
·
Barclays
LifeStance upgraded to Buy from Neutral at UBS
$8.50
(was $6.06)
Kevin Caliendo
·
UBS